|
Volume 7, Number 2
Cholesterol Metabolism and Suicidality
Most completed suicides occur within the context of a psychiatric illness, primarily major depressive disorder comorbid with substance disorders, and they are frequently associated with impulsive-aggressive behaviors. Read More
Predictors of SSRI Response: Efficacy and Adverse Effects
An accurate method of predicting the response to antidepressant therapy could improve treatment planning as well as treatment response. Read More
Identifying Risk Factors for Benzodiazepine Dependence
The outcome of benzodiazepine (BZD) use in clinical practice would improve greatly from the availability of a set of easily recognizable risk factors that could be used to identify patients who are prone for BZD dependence. Read More
Vagus Nerve Stimulation for Treatment-resistant Depression
Vagus nerve stimulation (VNS) therapy was recently approved by the US Food and Drug Administration (FDA) for use in patients with treatment-resistant depression (TRD). Read More
|
from Recent Issues
Current Pharmacological Treatments for Obsessive-Compulsive Disorder
Alexander Bystritsky, MD
SYNOPSIS | PDF
Risk Management Regulatory Concerns: The Evolving Legal Framework for Chemical Restraints
Debra A. Pinals, MD, and Paul S. Appelbaum, MD
SYNOPSIS | PDF
Pharmacological Treatment of Social Anxiety Disorder
Raquel Carmona, MD, Muhammad Saqlain Raza, MD, and Carlos Blanco, MD, PhD
SYNOPSIS | PDF
Special Report
When SSRIs Fail: A Review of Switching Strategies in Patients Resistant to an Initial SSRI
Charles DeBattista, DMH, MD, and Hugh Brent Solvason, PhD, MD
SYNOPSIS | PDF
Interview
Malpractice Risk Issues of Informed Consent
featuring Joseph DiGiacomo, MD
SYNOPSIS | PDF
|
|
View larger cover.
| Experience Essential Psychopharmacology, SUBSCRIBE today! |
|
)
